drugset / Trial / NCT01213238
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to the liver. The safety of these drug combinations will also be studied.
Timeline
- Start
- 2010-09-30
- Primary completion
- 2018-09-26
- Completion
- 2018-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 500 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 140 mg/m2 | Other |